# Petrelintide and ZUPREME-2 Canonical: https://europeanpeptideshop.com/blog/petrelintide-zupreme-2-amylin-results/ Explore the catalogue and research library. Ordering and shipping have not opened yet. Research news · 8 November 2026 · 3 min read · By [European Peptide Shop](https://europeanpeptideshop.com/about/) ### On this page Petrelintide is an investigational long-acting amylin analog. Zealand Pharma's October 7 announcement reported positive ZUPREME-2 results from a US-based study in people with overweight or obesity and type 2 diabetes. The trial compared petrelintide with placebo, not directly with semaglutide or tirzepatide. [1](https://attachment.news.eu.nasdaq.com/a79458d0c55563548f24baa344be1b901) ## How is petrelintide different from GLP-1 drugs? Zealand identifies petrelintide, formerly ZP8396, as an amylin analog. Its pipeline distinguishes the standalone program from a separate planned combination with CT-388. The molecule's name and development program should stay attached to the evidence being discussed. [3](https://www.zealandpharma.com/pipeline/petrelintide/) Amylin and GLP-1 are different biological targets. Similar headlines about weight change do not make compounds versions of the same medicine or establish that a result for one can be transferred to another. ## What was the study design? The registry for NCT06926842 describes a randomized, double-blind, placebo-controlled Phase 2 trial. Its primary outcome was percentage body-weight change at week 28. The public record's latest posted update is September 9 and lists the study as completed. [2](https://clinicaltrials.gov/study/NCT06926842) The company release describes 220 participants, while the registry lists 221 actual participants. Those source figures are retained as reported; the available summaries do not establish why they differ. [1](https://attachment.news.eu.nasdaq.com/a79458d0c55563548f24baa344be1b901) [2](https://clinicaltrials.gov/study/NCT06926842) ## What outcomes were announced? The company reported up to 9.2% average weight reduction with petrelintide versus 2.0% with placebo at 28 weeks using the efficacy estimand. It also reported discontinuation due specifically to gastrointestinal adverse events of 1.9% versus 1.7%. Those percentages describe a particular adverse-event category, not all reasons for stopping treatment. [1](https://attachment.news.eu.nasdaq.com/a79458d0c55563548f24baa344be1b901) Reported item | What it answers Weight change at 28 weeks | The trial's defined primary assessment GI-related discontinuation | Stopping treatment for gastrointestinal adverse events Placebo comparison | The tested control; not a comparison with another active medicine Full results still to be presented | The evidence stage described in the October announcement [1](https://attachment.news.eu.nasdaq.com/a79458d0c55563548f24baa344be1b901) [2](https://clinicaltrials.gov/study/NCT06926842) ## Does this establish an advantage over other peptides? No active-drug comparison was built into ZUPREME-2. Comparing its headline percentage with a different trial would require accounting for the population, duration, background therapy and analysis. A smaller or larger number alone does not supply a head-to-head result. [2](https://clinicaltrials.gov/study/NCT06926842) The same caution applies to tolerability. A low percentage for one reason for discontinuation cannot be treated as a complete safety assessment or compared casually with an all-adverse-event figure from another study. ## What comes after ZUPREME-2? The company reports that Phase 3 development has started. Its pipeline still identifies petrelintide as investigational. [1](https://attachment.news.eu.nasdaq.com/a79458d0c55563548f24baa344be1b901) [3](https://www.zealandpharma.com/pipeline/petrelintide/) Later reporting should keep those trials separate and examine whether their predefined outcomes are met. Regulatory approval, availability and broad comparative claims would need their own evidence; they do not follow automatically from this Phase 2 announcement. ## Scope for European readers This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the [research-use statement](https://europeanpeptideshop.com/research-use/) for the storefront's scope. ## Laboratory research only Materials listed on this site are supplied for in-vitro laboratory research and are not for use in or on humans or animals. They are not medicines. This article summarises published work and gives no dosing, administration, treatment or in-vivo guidance. Findings from a study apply to the material and conditions of that study, and they say nothing about any product listed here. ## References - [Zealand Pharma: ZUPREME-2 company announcement, October 7, 2026](https://attachment.news.eu.nasdaq.com/a79458d0c55563548f24baa344be1b901) - [Zealand Pharma: petrelintide pipeline](https://www.zealandpharma.com/pipeline/petrelintide/) - [ClinicalTrials.gov: ZUPREME-2, NCT06926842](https://clinicaltrials.gov/study/NCT06926842) ## More articles Research news · 2 min read ## [Australia's Synedica peptide warning](https://europeanpeptideshop.com/blog/synedica-tga-warning-australia-tb-500/) Australian testing found Synedica peptide products contained no TB-500 and less retatrutide than labelled. The TGA has told Australians to discard them. 8 November 2026 Research news · 3 min read ## [Avexitide and the LUCIDITY trial](https://europeanpeptideshop.com/blog/avexitide-glp-1-antagonist-lucidity/) Why does avexitide block GLP-1? Explore post-bariatric hypoglycemia, LUCIDITY results and Amylyx’s November 2026 FDA-filing and conference plans. 8 November 2026 Research news · 3 min read ## [BPC-157: UK and US regulatory context](https://europeanpeptideshop.com/blog/is-bpc-157-legal-in-the-uk/) The October 2026 US peptide policy is not UK authorisation. Read the MHRA classification framework and why research-use wording cannot settle a product's. 8 November 2026